Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Checkmate Pharmaceuticals stock
Learn how to easily invest in Checkmate Pharmaceuticals stock.
Checkmate Pharmaceuticals Inc is a biotechnology business based in the US. Checkmate Pharmaceuticals shares (CMPI) are listed on the NASDAQ and all prices are listed in US Dollars. Checkmate Pharmaceuticals employs 28 staff and has a market cap (total outstanding shares value) of 0.00.
How to buy shares in Checkmate Pharmaceuticals
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CMPI – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Checkmate Pharmaceuticals stock price (NASDAQ: CMPI)Use our graph to track the performance of CMPI stocks over time.
Checkmate Pharmaceuticals shares at a glance
|Latest market close||$2.54|
|52-week range||$2.52 - $17.85|
|50-day moving average||$3.50|
|200-day moving average||$5.36|
|Wall St. target price||$18.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-2.73|
Buy Checkmate Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Checkmate Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Checkmate Pharmaceuticals price performance over time
|1 week (2022-01-10)||-5.41%|
|1 month (2021-12-16)||-18.75%|
|3 months (2021-10-15)||-38.17%|
|6 months (2021-07-16)||-50.68%|
|1 year (2021-01-15)||-80.85%|
|2 years (2020-01-13)||N/A|
|3 years (2019-01-13)||N/A|
|5 years (2017-01-13)||N/A|
Checkmate Pharmaceuticals financials
|Gross profit TTM||$0|
|Return on assets TTM||-31.65%|
|Return on equity TTM||-54.44%|
|Market capitalisation||$55.8 million|
TTM: trailing 12 months
Checkmate Pharmaceuticals share dividends
We're not expecting Checkmate Pharmaceuticals to pay a dividend over the next 12 months.
Checkmate Pharmaceuticals overview
Checkmate Pharmaceuticals, Inc. , a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts. .
Checkmate Pharmaceuticals in the news
Supreme Court vaccine mandate ruling won't bar companies from demanding Covid shots for workers — Biden vows to advocate for that
Two of Sen. Kyrsten Sinema's former aides have lobbied for corporate giants looking to influence Joe Biden's agenda
One Checkmate Pharmaceuticals, Inc. (NASDAQ:CMPI) insider upped their stake by 2.5% in the previous year
Frequently asked questionsWhat percentage of Checkmate Pharmaceuticals is owned by insiders or institutions?
Currently 10.922% of Checkmate Pharmaceuticals shares are held by insiders and 83.756% by institutions. How many people work for Checkmate Pharmaceuticals?
Latest data suggests 28 work at Checkmate Pharmaceuticals. When does the fiscal year end for Checkmate Pharmaceuticals?
Checkmate Pharmaceuticals's fiscal year ends in December. Where is Checkmate Pharmaceuticals based?
Checkmate Pharmaceuticals's address is: 245 Main Street, Cambridge, MA, United States, 02142 What is Checkmate Pharmaceuticals's ISIN number?
Checkmate Pharmaceuticals's international securities identification number is: US1628181083
More guides on Finder
Donut savings review
Donut earns up to 10% APY, but you must have an iOS device.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
NFT-funded LinksDAO moves $10.5 million closer to buying a golf course
Creating a golf club is a thus-far unique application of NFTs, and another step forward for the decentralized economy.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
How to buy HeartCore Enterprises (HTCR) stock when it goes public
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
Ask an Expert